Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer

Prior treatment

• Have previously received chemotherapy or radiation other than the first cycle of the planned adjuvant or neoadjuvant chemotherapy as indicated in Inclusion #5

Other illness

• Uncontrolled intercurrent illness/medical condition or psychiatric illness/social situations that would limit compliance with study requirements as determined by the investigator
• Diagnosis of distant metastatic breast cancer
• Diagnosis of a chronic pain syndrome (e.g. fibromyalgia, severe osteoarthritis, etc.)

Other

• Subjects meeting any of the criteria below may not participate in the study:
• Taking chronic narcotics, as determined by treating physician
• A baseline ESAS pain score of greater than 8.

• Subject must meet all the following applicable inclusion criteria to participate in this study:
• Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately.
• Age ≥ 18 years at the time of consent
• Female
• Histological or cytological confirmation of invasive breast cancer.
• Planned to undergo adjuvant or neoadjuvant chemotherapy treatment for invasive breast cancer AND pegfilgrastim (or biosimilar substitution) treatment for neutropenic prophylaxis.
• Ability to read and understand the English and/or Spanish language
• As determined by the enrolling physician, ability of the subject to understand and comply with study procedures for the entire length of the study